What is the common abbreviation for Bedaquiline/Snaery and how to remember it?

Bedaquiline (Bedaquiline) is a new anti- tuberculosis drug, mainly used to treat patients with multidrug-resistant tuberculosis (MDR-TB). Its common abbreviation is BDQ, which is widely used in global medical literature, pharmacological databases, and World Health Organization (WHO) technical reports. The abbreviation is derived from the first letter "B", the key consonant "D" in the middle, and the ending "Q" of its English name "Bedaquiline". It is simple and clear and can be easily identified in drug management and scientific research documents. In order to make it easier to remember, clinical pharmacists usually suggest that "BDQ" be associated with "Bedaquiline Drug for Quick TB control", which not only retains the characteristics of the drug name, but also highlights its anti-tuberculosis efficacy.

The development of bedaquiline is an important milestone in the history of tuberculosis treatment. Since being approved by the U.S. FDA in 2012, it has become the first new class of oral drug approved for tuberculosis in the past 40 years and belongs to the dichloroquinoline anti-tuberculosis drugs. Its mechanism of action is by inhibiting the energy production of Mycobacterium tuberculosis ATP synthase (ATP synthase), thereby blocking the energy supply required for bacterial survival. Unlike traditional drugs, bedaquiline targets novel targets and is not prone to cross-talk with other drug resistance mechanisms, making it uniquely valuable in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

In the field of global tuberculosis control,the abbreviation BDQ has become a standard terminology in international research, guidelines and clinical communication. In addition, to facilitate identification by patients and medical staff, its trade name "Sirturo" is often mentioned in international clinical trials. When combined with abbreviation memory, "Sirturo-BDQ" can be used as a complete impression - the former is brand recognition, and the latter is a common pharmacological abbreviation. Double memory helps avoid confusion.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline